ARTIVION, INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Davis John E | Chief Commercial Officer | Sale | 5,000 | $45.11 | $225,550 | Dec 15, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Sale | 4,572 | $44.42 | $203,088 | Dec 8, 2025 |
| Mackin James P | President & CEO | Option Exercise | 30,921 | $29.62 | $915,880 | Dec 3, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 5,267 | $45.30 | $238,595 | Dec 3, 2025 |
| Mackin James P | President & CEO | Option Exercise | 30,921 | $29.62 | $915,880 | Dec 2, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Gift | 750 | — | — | Dec 1, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Option Exercise | 27,075 | $11.03 | $298,637 | Nov 21, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 11,888 | $44.14 | $524,736 | Nov 20, 2025 |
| Hoff Elizabeth A | — | Sale | 4,200 | $45.10 | $189,420 | Nov 18, 2025 |
| Davis John E | Chief Commercial Officer | Option Exercise | 6,393 | $29.62 | $189,361 | Nov 17, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Sale | 6,000 | $45.73 | $274,380 | Nov 17, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 6,394 | $45.17 | $288,817 | Nov 14, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Sale | 3,482 | $45.86 | $159,685 | Nov 13, 2025 |
| Davis John E | Chief Commercial Officer | Sale | 6,563 | $45.86 | $300,979 | Nov 13, 2025 |
| Mackin James P | President & CEO | Sale | 34,210 | $45.86 | $1,568,871 | Nov 13, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 5,761 | $45.86 | $264,199 | Nov 13, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 4,993 | $45.86 | $228,979 | Nov 13, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 2,960 | $44.62 | $132,075 | Nov 11, 2025 |
| Mackin James P | President & CEO | Sale | 17,580 | $44.62 | $784,420 | Nov 10, 2025 |
| Davis John E | Chief Commercial Officer | Sale | 3,373 | $44.62 | $150,503 | Nov 10, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Sale | 1,789 | $44.62 | $79,825 | Nov 10, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 2,566 | $44.62 | $114,495 | Nov 10, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 18,200 | $44.02 | $801,164 | Aug 27, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 10,000 | $44.37 | $443,700 | Aug 25, 2025 |
| Mackin James P | President & CEO | Sale | 12,500 | $42.32 | $529,000 | Aug 15, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 16,975 | $43.01 | $730,095 | Aug 12, 2025 |
| Davis John E | Chief Commercial Officer | Option Exercise | 10,802 | $26.24 | $283,444 | Aug 12, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Option Exercise | 7,992 | $29.62 | $236,723 | Aug 8, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 1,236 | $29.50 | $36,462 | Jun 17, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 1,826 | $28.43 | $51,913 | Jun 13, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 8,748 | $29.00 | $253,692 | May 27, 2025 |
| SEMEDO ANTHONY B. | — | Sale | 2,600 | $28.47 | $74,022 | May 23, 2025 |
| SEMEDO ANTHONY B. | — | Sale | 2,600 | $28.47 | $74,022 | May 23, 2025 |
| SEMEDO ANTHONY B. | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Borgstrom Marna P | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| BEVEVINO DANIEL J | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| ACKERMAN THOMAS F | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Salveson Jon W | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Hoff Elizabeth A | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Burbank Jeffrey H | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Bullock James | — | Award / Grant | 6,325 | — | — | May 22, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 9,926 | $29.00 | $287,854 | May 21, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 5,737 | $29.13 | $167,119 | May 9, 2025 |
| Holloway Jean F | SVP, General Counsel | Sale | 18,020 | $23.61 | $425,452 | Mar 11, 2025 |
| Davis John E | Chief Commercial Officer | Option Exercise | 15,910 | $21.55 | $342,861 | Mar 11, 2025 |
| Mackin James P | President & CEO | Sale | 17,739 | $24.80 | $439,927 | Mar 6, 2025 |
| Horton Amy | VP, Chief Accounting Officer | Award / Grant | 10,261 | — | — | Mar 6, 2025 |
| Berry Lance A | Executive VP, CFO | Award / Grant | 48,100 | — | — | Mar 6, 2025 |
| Davis John E | Chief Commercial Officer | Award / Grant | 25,654 | — | — | Mar 6, 2025 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Sale | 1,603 | $24.80 | $39,754 | Mar 6, 2025 |